Research
Sell
A Sell rating means lf0 research identifies a meaningful gap between a companys current valuation and its underlying fundamentals, typically driven by decelerating growth, margin pressure, balance-sheet risk, or a competitive position eroding faster than the market has priced in. Sell-rated companies carry a risk/reward skew that favors caution over the timeframe of the analysis.




The Scorecard: MYRG Sell — Correct so far
Revisiting our Sell call on MYRG: entry $391.51, latest $309.39, -21.0%.
NexGen Energy Stock Analysis: Buy or Sell? Valuation, Cash Burn & Liquidity
NexGen Energy Ltd. (NXE) is rated Sell as the company is still funding growth ahead of durable cash generation. Despite a recent EBITDA rebound, negative…
The Scorecard: ONTO Sell — Correct so far
Revisiting our Sell call on ONTO: entry $319.32, latest $292.62, -8.4%.
The Scorecard: HUT Sell — Correct so far
Revisiting our Sell call on HUT: entry $98.33, latest $87.13, -11.4%.
The Scorecard: AMBA Sell — Correct so far
Revisiting our Sell call on AMBA: entry $72.90, latest $71.16, -2.4%.
The Scorecard: TPL Sell — Correct so far
Revisiting our Sell call on TPL: entry $408.92, latest $369.40, -9.7%.
The Scorecard: CIFR Sell — Correct so far
Revisiting our Sell call on CIFR: entry $21.85, latest $16.02, -26.7%.
The Scorecard: MTZ Sell — Correct so far
Revisiting our Sell call on MTZ: entry $380.63, latest $248.73, -34.7%.
Sphere Entertainment Stock Analysis: Buy or Sell? Valuation, Debt & Cash Flow
Sphere Entertainment Co. (SPHR) is rated Hold as real free cash flow offsets a still-negative operating margin and a rich valuation. Debt load and the…
Altimmune Stock Analysis: Buy or Sell? Valuation, Cash Burn & Phase 3
Altimmune (ALT) is rated Sell as the stock already prices in Phase 3 success while the business remains pre-revenue. Despite $326.3 million in cash and…
Most Popular Research